Trial Outcomes & Findings for Transcranial Direct Current Stimulation Potentiation of Fear Extinction in OCD (NCT NCT05521074)
NCT ID: NCT05521074
Last Updated: 2026-09-04
Results Overview
Greater reduction in the difference in frontomedial theta event-related spectral perturbation (ERSP) between CS+ vs CS- indicates more complete neural extinction of the conditioned fear response, reflecting diminished differential threat processing such that the previously conditioned stimulus is being processed more similarly to the safe stimulus.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
86 participants
Primary outcome timeframe
Extinction Recall Phase (Day 2)
Results posted on
2026-09-04
Participant Flow
Participant milestones
| Measure |
Active tDCS Administered Before Extinction Phase
The investigators will stimulate using 2mA of direct current during 20 min before the extinction phase of the fear conditioning and extinction paradigm.
|
Active tDCS Administered During Extinction Phase
The investigators will stimulate using 2mA of direct current during 20 min during the extinction phase of the fear conditioning and extinction paradigm.
|
Active tDCS Administered After Extinction Phase
The investigators will stimulate using 2mA of direct current during 20 min after the extinction phase of the fear conditioning and extinction paradigm.
|
Sham tDCS
Sham will consist of a ramp up and down of activity (from 0 to 2mA and back to 0mA) in the first 30sec and again in the last 30 sec of the 20min stimulation period (which will occur before/during/after the extinction phase). No active tDCS will occur.
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
21
|
22
|
21
|
22
|
|
Overall Study
COMPLETED
|
21
|
19
|
21
|
22
|
|
Overall Study
NOT COMPLETED
|
0
|
3
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Transcranial Direct Current Stimulation Potentiation of Fear Extinction in OCD
Baseline characteristics by cohort
| Measure |
Active tDCS Administered Before Extinction Phase
n=21 Participants
The investigators will stimulate using 2mA of direct current during 20 min before the extinction phase of the fear conditioning and extinction paradigm.
|
Active tDCS Administered During Extinction Phase
n=22 Participants
The investigators will stimulate using 2mA of direct current during 20 min during the extinction phase of the fear conditioning and extinction paradigm.
|
Active tDCS Administered After Extinction Phase
n=21 Participants
The investigators will stimulate using 2mA of direct current during 20 min after the extinction phase of the fear conditioning and extinction paradigm.
|
Sham tDCS
n=22 Participants
Sham will consist of a ramp up and down of activity (from 0 to 2mA and back to 0mA) in the first 30sec and again in the last 30 sec of the 20min stimulation period (which will occur before/during/after the extinction phase). No active tDCS will occur.
|
Total
n=86 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Continuous
|
30.0 years
STANDARD_DEVIATION 9.8 • n=23 Participants
|
28.0 years
STANDARD_DEVIATION 10.4 • n=23 Participants
|
26.3 years
STANDARD_DEVIATION 5.6 • n=22 Participants
|
24.1 years
STANDARD_DEVIATION 3.4 • n=21 Participants
|
27.1 years
STANDARD_DEVIATION 8.0 • n=24 Participants
|
|
Sex/Gender, Customized
Sex · Male
|
3 Participants
n=23 Participants
|
8 Participants
n=23 Participants
|
5 Participants
n=22 Participants
|
4 Participants
n=21 Participants
|
20 Participants
n=24 Participants
|
|
Sex/Gender, Customized
Sex · Female
|
18 Participants
n=23 Participants
|
14 Participants
n=23 Participants
|
16 Participants
n=22 Participants
|
17 Participants
n=21 Participants
|
65 Participants
n=24 Participants
|
|
Sex/Gender, Customized
Sex · Prefer not to answer
|
0 Participants
n=23 Participants
|
0 Participants
n=23 Participants
|
0 Participants
n=22 Participants
|
1 Participants
n=21 Participants
|
1 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=23 Participants
|
2 Participants
n=23 Participants
|
0 Participants
n=22 Participants
|
1 Participants
n=21 Participants
|
4 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
20 Participants
n=23 Participants
|
20 Participants
n=23 Participants
|
21 Participants
n=22 Participants
|
21 Participants
n=21 Participants
|
82 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=23 Participants
|
0 Participants
n=23 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=24 Participants
|
|
Race/Ethnicity, Customized
Race · White
|
15 Participants
n=23 Participants
|
14 Participants
n=23 Participants
|
16 Participants
n=22 Participants
|
18 Participants
n=21 Participants
|
63 Participants
n=24 Participants
|
|
Race/Ethnicity, Customized
Race · Black/African American
|
0 Participants
n=23 Participants
|
0 Participants
n=23 Participants
|
1 Participants
n=22 Participants
|
2 Participants
n=21 Participants
|
3 Participants
n=24 Participants
|
|
Race/Ethnicity, Customized
Race · Asian
|
5 Participants
n=23 Participants
|
2 Participants
n=23 Participants
|
3 Participants
n=22 Participants
|
1 Participants
n=21 Participants
|
11 Participants
n=24 Participants
|
|
Race/Ethnicity, Customized
Race · More than one race
|
1 Participants
n=23 Participants
|
3 Participants
n=23 Participants
|
1 Participants
n=22 Participants
|
1 Participants
n=21 Participants
|
6 Participants
n=24 Participants
|
|
Race/Ethnicity, Customized
Race · American Indian or Alaska Native
|
0 Participants
n=23 Participants
|
0 Participants
n=23 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=24 Participants
|
|
Race/Ethnicity, Customized
Race · Another race
|
0 Participants
n=23 Participants
|
2 Participants
n=23 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=21 Participants
|
2 Participants
n=24 Participants
|
|
Race/Ethnicity, Customized
Race · Native Hawaiian or Pacific Islander
|
0 Participants
n=23 Participants
|
0 Participants
n=23 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=24 Participants
|
|
Race/Ethnicity, Customized
Race · Unknown/not reported
|
0 Participants
n=23 Participants
|
1 Participants
n=23 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=24 Participants
|
|
Region of Enrollment
United States
|
21 Participants
n=23 Participants
|
22 Participants
n=23 Participants
|
21 Participants
n=22 Participants
|
22 Participants
n=21 Participants
|
86 Participants
n=24 Participants
|
|
Y-BOCS
|
19.9 Scores on a scale
STANDARD_DEVIATION 4.6 • n=23 Participants
|
20.2 Scores on a scale
STANDARD_DEVIATION 5.1 • n=23 Participants
|
19.2 Scores on a scale
STANDARD_DEVIATION 3.7 • n=22 Participants
|
21.0 Scores on a scale
STANDARD_DEVIATION 4.3 • n=21 Participants
|
20.1 Scores on a scale
STANDARD_DEVIATION 4.4 • n=24 Participants
|
PRIMARY outcome
Timeframe: Extinction Recall Phase (Day 2)Population: Participants (n=11) were excluded from EEG analyses for the following reasons: poor data quality (n=6); participant dropped out (n=3); EEG data/triggers missing (n=2).
Greater reduction in the difference in frontomedial theta event-related spectral perturbation (ERSP) between CS+ vs CS- indicates more complete neural extinction of the conditioned fear response, reflecting diminished differential threat processing such that the previously conditioned stimulus is being processed more similarly to the safe stimulus.
Outcome measures
| Measure |
Active tDCS Administered Before Extinction Phase
n=19 Participants
The investigators will stimulate using 2mA of direct current during 20 min before the extinction phase of the fear conditioning and extinction paradigm.
|
Active tDCS Administered During Extinction Phase
n=17 Participants
The investigators will stimulate using 2mA of direct current during 20 min during the extinction phase of the fear conditioning and extinction paradigm.
|
Active tDCS Administered After Extinction Phase
n=19 Participants
The investigators will stimulate using 2mA of direct current during 20 min after the extinction phase of the fear conditioning and extinction paradigm.
|
Sham tDCS
n=20 Participants
Sham will consist of a ramp up and down of activity (from 0 to 2mA and back to 0mA) in the first 30sec and again in the last 30 sec of the 20min stimulation period (which will occur before/during/after the extinction phase). No active tDCS will occur.
|
|---|---|---|---|---|
|
Difference in Frontomedial Theta Power (EEG) to the Conditioned Stimulus (CS+) Versus the Unconditioned Stimulus (CS-) Between tDCS Conditions During Extinction Recall
|
-0.30 Decibel (dB)
Standard Deviation 1.4
|
-0.83 Decibel (dB)
Standard Deviation 2.0
|
-0.26 Decibel (dB)
Standard Deviation 1.8
|
-0.37 Decibel (dB)
Standard Deviation 1.8
|
PRIMARY outcome
Timeframe: Extinction Recall Phase (Day 2)Population: Participants (n=19) were excluded from SC analyses for the following reasons: poor data quality (n=6); participant dropped out (n=3); SC equipment error (n=1); SC non-responders (i.e., individuals with a mean unconditioned SCR of less than 0.1 μS; n=9).
Higher skin conductance (microSiemens) indicates greater fear intensity.
Outcome measures
| Measure |
Active tDCS Administered Before Extinction Phase
n=16 Participants
The investigators will stimulate using 2mA of direct current during 20 min before the extinction phase of the fear conditioning and extinction paradigm.
|
Active tDCS Administered During Extinction Phase
n=16 Participants
The investigators will stimulate using 2mA of direct current during 20 min during the extinction phase of the fear conditioning and extinction paradigm.
|
Active tDCS Administered After Extinction Phase
n=18 Participants
The investigators will stimulate using 2mA of direct current during 20 min after the extinction phase of the fear conditioning and extinction paradigm.
|
Sham tDCS
n=17 Participants
Sham will consist of a ramp up and down of activity (from 0 to 2mA and back to 0mA) in the first 30sec and again in the last 30 sec of the 20min stimulation period (which will occur before/during/after the extinction phase). No active tDCS will occur.
|
|---|---|---|---|---|
|
Difference in the Square Root Skin Conductance Response (SCR) to the Conditioned Stimulus (CS+) Versus the Unconditioned Stimulus (CS-) Between tDCS Conditions During the First 12 Trials of Extinction Recall
|
0.13 microSiemens
Standard Deviation 0.35
|
0.24 microSiemens
Standard Deviation 0.42
|
0.17 microSiemens
Standard Deviation 0.38
|
0.24 microSiemens
Standard Deviation 0.43
|
Adverse Events
Active tDCS Administered Before Extinction Phase
Serious events: 0 serious events
Other events: 21 other events
Deaths: 0 deaths
Active tDCS Administered During Extinction Phase
Serious events: 0 serious events
Other events: 21 other events
Deaths: 0 deaths
Active tDCS Administered After Extinction Phase
Serious events: 0 serious events
Other events: 21 other events
Deaths: 0 deaths
Sham tDCS
Serious events: 0 serious events
Other events: 21 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Active tDCS Administered Before Extinction Phase
n=21 participants at risk
The investigators will stimulate using 2mA of direct current during 20 min before the extinction phase of the fear conditioning and extinction paradigm.
|
Active tDCS Administered During Extinction Phase
n=22 participants at risk
The investigators will stimulate using 2mA of direct current during 20 min during the extinction phase of the fear conditioning and extinction paradigm.
|
Active tDCS Administered After Extinction Phase
n=21 participants at risk
The investigators will stimulate using 2mA of direct current during 20 min after the extinction phase of the fear conditioning and extinction paradigm.
|
Sham tDCS
n=22 participants at risk
Sham will consist of a ramp up and down of activity (from 0 to 2mA and back to 0mA) in the first 30sec and again in the last 30 sec of the 20min stimulation period (which will occur before/during/after the extinction phase). No active tDCS will occur.
|
|---|---|---|---|---|
|
General disorders
Sleepiness
|
47.6%
10/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
40.9%
9/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
38.1%
8/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
50.0%
11/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
|
Musculoskeletal and connective tissue disorders
Neck Pain
|
14.3%
3/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
13.6%
3/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
4.8%
1/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
4.5%
1/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
|
Nervous system disorders
Headache
|
14.3%
3/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
31.8%
7/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
33.3%
7/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
22.7%
5/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
|
Nervous system disorders
Restlessness/Difficulty Concentrating
|
57.1%
12/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
36.4%
8/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
38.1%
8/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
27.3%
6/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
|
Skin and subcutaneous tissue disorders
Redness/Irritation
|
9.5%
2/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
22.7%
5/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
14.3%
3/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
4.5%
1/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
|
Skin and subcutaneous tissue disorders
Scalp Pain
|
38.1%
8/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
18.2%
4/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
33.3%
7/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
54.5%
12/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
|
Skin and subcutaneous tissue disorders
Tingling/Burning/Itching Sensation
|
95.2%
20/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
77.3%
17/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
90.5%
19/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
81.8%
18/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
|
Musculoskeletal and connective tissue disorders
Muscle Soreness
|
4.8%
1/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
9.1%
2/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
4.8%
1/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
0.00%
0/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
|
Psychiatric disorders
Increased Anxiety
|
4.8%
1/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
9.1%
2/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
9.5%
2/21 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
13.6%
3/22 • From enrollment (virtual consent) until final study visit (Day 2)
At the start of the experimental visits, participants were asked about any major physical health problems/injuries, seeing a physical or mental health provider, hospitalizations, or any other major problems/concerns. At the end of the experimental visits, they were asked if they experienced any of the side effects of tDCS included on a 10-item list. The PI reviewed each AE during weekly study meetings to discuss relatedness to the study, severity, and corrective actions.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place